Acenocoumarol stabilization is delayed in CYP2C9*3 carriers

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 5, 2004, Pages 394-402

  Schalekamp, Tom ^a   Van Geest Daalderop, Johanna H H ^b   De Vries Goldschmeding, Hanneke ^b   Conemans, Jean ^b   Bernsen, M J ^b   De Boer, Anthonius ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; CYTOCHROME P450 2C9;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG STABILITY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL STANDARD UNIT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTPATIENT DEPARTMENT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WILD TYPE;

ACENOCOUMAROL; AGED; AGED, 80 AND OVER; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION DISORDERS; DNA PRIMERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; NETHERLANDS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES;

EID: 2042478066     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.12.017     Document Type: Article

References (33)

1. Hirsch J., Dalen J.E., Anderson D.R., Poller L., Bussey H., Ansell J., et al. Oral anticoagulants mechanism of action, clinical effectiveness and optimal therapeutic range. Chest. 119:2001;8S-21S
2. Penning-van Beest F.J.A., van Meegen E., Rosendaal F.R., Stricker B.H.C. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost. 86:2001;569-574
3. Aithal G.P., Day C.P., Kesteven P.J., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 353:1999;717-719
4. Freeman B.D., Zehnbauer B.A., McGrath S., Borecki I., Buchman T.G. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery. 128:2000;281-285
5. Margaglione M., Colaizzo D., D'Andrea G., Brancaccio V., Ciampa A., Grandone E., et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 84:2000;775-778
6. Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 96:2000;1816-1819
7. Higashi M.K., Veenstra D.L., Midori Konto L., Wittkowsky A.K., Srinouanprachan S.L., Farin F.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 287:2002;1690-1698
8. Scordo M.G., Pengo V., Spina E., Dahl M.-L., Gusella M., Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 72:2002;702-710
9. Ablin J., Cabili S., Lagziel A., Peretz H. Warfarin therapy in a patient homozygous for the CYP2C9*3 allele. Isr Med Assoc J. 4:2002;139-141
10. Bloch A., Ben-Chetrit E., Muszkat M., Caraco Y. Major bleeding caused by warfarin in a genetically susceptible patient. Pharmacotherapy. 22:2002;97-101
11. Thijssen H.H.W., Flinois J.-P., Beaune P. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos. 28:2000;1284-1290
12. Thijssen H.H.W., Verkooijen I.W.C., Frank H.L.L. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics. 10:2000;757-760
13. Hermida J., Zarza J., Alberca I., Lopez M.L., Molina E., Rocha E. Differential effects of 2C9*3 and 2C9*2 allelic variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood. 99:2002;4237-4239
14. Tassies D., Freire C., Pijoan J., Maragalli S., Monteagudo J., Ordinas A., et al. Pharmacogenetics of acenocoumarol cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica. 87:2002;1185-1191
15. Verstuyft C., Morin S., Robert A., Loriot M.A., Beaune P., Jaillon P., et al. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics. 11:2001;735-737
16. Anonymous. Standaard Afhandeling Coumarine-interacties. Edited Federatie van Nederlandse Trombosediensten (Dutch, ISBN 90-80082-2-5); 1999. Available from: URL: www.fnt.nl
17. Takahashi H., Sato T., Shimoyama Y., Shioda N., Shimizu T., Kubo S., et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther. 66:1999;569-581
18. Steward D., Haining R., Henne K., Davis G., Rushmore T., Trager W.F., et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 7:1997;361-367
19. Sullivan-Klose T., Ghanayem B., Bell D., Zhang Z., Kaminsky L., Shenfield G., et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 6:1996;341-349
20. Cannegieter S., Rosendaal F.R., Wintzen A., van der Meer F.J., Vandenbroucke J.P., Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 333:1995;11-17
21. Hylek E.M., Chang Y., Skates S.J., Hughes R.A., Singer D.E. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med. 160:2000;1612-1617
22. van der Meer F.J., Rosendaal F.R., Vandenbroucke J.P., Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost. 76:1996;12-16
23. Visser L.E., Penning-van Beest F.J.A., Kasbergen H.A.A., De Smet P.A.G.M., Vulto A.G., Hofman A., et al. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. Clin Pharmacol Ther. 71:2002;496-502
24. Penning-van Beest F.J.A., van Meegen E., Rosendaal F.R., Stricker B.H.C. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther. 69:2001;451-457
25. Miners J.O., Birkett D.J. Cytochrome P4502C9 an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 45:1998;525-538
26. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C9 subfamily. Br J Clin Pharmacol. 52:2001;349-355
27. Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorphisms a comprehensive review of the in-vitro and human data. Pharmacogenetics. 12:2002;251-263
28. Xie H.-G., Prasad H.C., Kim R.B., Stein C.M. CYP2C9 allelic variants ethnic distribution and functional significance. Adv Drug Deliv Rev. 54:2002;1257-1270
29. Godbillon J., Richard J., Gerardin A., Meinertz T., Kasper W., Jahnchen E. Pharmacokinetics of the enantiomers of acenocoumarol in man. Br J Clin Pharmacol. 12:1981;621-629
30. Thijssen H.H.W., Drittij M.-J., Vervoort L.M.T., De Vries-Hanje J.C. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clin Pharmacol Ther. 70:2001;292-298
31. Wen X., Wang J.-S., Backmann J.T., Laitila J., Neuvonen P.J. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 30:2002;631-635
32. Naganuma M., Shiga T., Nishikata K., Tsuchiya T., Kasanuki H., Fujii E. Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J Cardiovasc Pharmacol Ther. 6:2001;363-367
33. Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 40:2001;587-603